Consensus on the Management of Liver Injury Associated with Targeted Drugs and Immune Checkpoint Inhibitors for Hepatocellular Carcinoma (Version 2024)
Suxian Zhao, Yuemin Nan(Hebei Medical University), Xiaoyuan Xu(Columbia University), Lingdi Liu(Hebei Medical University), Yanhang Gao(Jilin University), Hong You(Harbin Institute of Technology), Hui Zhuang(Institute of Crop Sciences), Mei Liu(Dana-Farber Cancer Institute), Yu Chen, Jie Li(Zhongyuan University of Technology), Sha Huang(University of Michigan), Zhongping Duan(Capital Medical University), Jidong Jia(National Clinical Research Center for Digestive Diseases), Jingfeng Liu(Fujian Medical University), Lai Wei(Nanjing University of Finance and Economics)
Cited by 1
Related Papers
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma
|Journal of Experimental & Clinical Cancer Research|2015|271